drugset / Trial / NCT05556616
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
RandomizedSequentialOpen-labelTreatment
Summary
The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp alfa. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.
Timeline
- Start
- 2023-01-12
- Primary completion
- 2024-06-04
- Completion
- 2024-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Subcutaneous |
| Subject | Carfilzomib | Other / unclassified | 70 mg/m2 | Intravenous |
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Modakafusp alfa | Protein / enzyme biologic | 80 mg | Intravenous |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |